NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
- Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
- “The results from our Alzheimer’s trial demonstrate that SNK01 has the potential to cross the blood-brain barrier as evidenced by the CSF biomarker data,” said Paul Y.
- The pressing need for effective Alzheimer’s treatments cannot be overstated, and we are committed to addressing this healthcare challenge.
- Based on the CSF biomarker data, intravenous SNK01 appears to cross the blood brain barrier to improve CSF AB42/40 and reduce pTau181 levels.